OVERVIEW of GUARDANT360
Your cancer genome changes in response to therapies.
Before Guardant 360, the only option available to understand these changes was to have repeated tissue biopsies.
Guardant360 is able to...
identify somatic mutations of 73 genes, proven to be clinically relevant, and reports on microsatellite instability (MSI) status through the detection of circulating tumor DNA (ctDNA) in blood specimens using NGS technologies.
Why use Guardant360®?
99.99% Analytical Specificity
Advantages of Guardant360
WHO is it SUITED for?
Advanced cancer patients who require complete genotyping
Insufficient tissue biopsy in quantity or quality, or tissue is unobtainable at diagnosis
Archived tissue older than 6 months
Unresponsive to one or more lines of therapy or intervention since the last biopsy
Time to treatment is critical and the decision is required within 2 weeks.
Patient who prefer non-invasive genomic profiling or is unwilling to undergo invasive biopsies.